Genetic Function – Page 2

Bausch + Lomb Enters Strategic Collaboration with City Therapeutics for RNAi-Based Eye Disease Treatment

3 months ago talkbio0Tagged Age related macular degeneration, Bausch, Cities, Geographic Atrophy, Lomb, RNA Interference, strategic collaboration

Bausch + Lomb, City Therapeutics, RNAi, eye disease, geographic atrophy, age-related macular degeneration, strategic collaboration

AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment

4 months ago talkbio0Tagged Approved, AstraZeneca, Epidermal Growth Factor Receptor, EU, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Tagrisso

AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment

FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns

4 months ago talkbio0Tagged Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, manufacturing issues, Mutation, Non-Small Cell Lung Carcinoma, Rejection, Subcutaneous Rybrevant, United States Food and Drug Administration

FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

4 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results

4 months ago talkbio0Tagged Carcinoma breast stage IV, Clinical Trials, Malignant neoplasm of breast, Mutation, PI3 K inhibitor, PI3Ka, Relay Therapeutics, RLY-2608

Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial

Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $10 Billion Collaboration for Rare Disease Treatments

5 months ago talkbio0Tagged Arrowhead, biotech, Collaboration, Drug Industry, Genetic Medicine, Infrequent, RNA Interference

Sarepta Therapeutics, Arrowhead Pharmaceuticals, RNAi, Rare Diseases, Genetic Medicine, Collaboration Agreement, Biotech, Pharmaceutical Industry

Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry

5 months ago talkbio0Tagged advancements, Aortic Valve Insufficiency, Biopharma, DNA Integration, Glucagon-Like Peptide 1, Health care facility, Healthcare technology, Impact food supplement, Ira (eukaryote), Pharmaceutical Industry Shifts, Telemedicine, trends qualifier, Value-Based Care

AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements